Advertisement

Topics

Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug

10:26 EDT 25 Mar 2019 | Labiotech.eu

The failure of Biogen’s Alzheimer’s disease drug in a phase III trial last week caused BioArctic’s stock price to plummet by 35% on Nasdaq Stockholm. The Swedish company has just begun a phase III trial of its own Alzheimer’s treatment. Last week, Biogen and its pharma collaborator Eisai discontinued the phase III development of an […]

The post Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug appeared first on Labiotech.eu.

Original Article: Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug

NEXT ARTICLE

More From BioPortfolio on "Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...